Table 1 The baseline characteristics between good outcome and death/severe disability groups

Age, y (Mean SD)

66.32 ± 9.97

68.68 ± 9.63

0.005

NIHSS score, median (IQR)

7(5–11)

13(10–16)

<0.001

D-dimer, median (IQR)

1.30(0.80–2.00)

2.50(1.60–3.88)

<0.001

INR, median (IQR)

1.34(1.06–1.97)

1.37(1.10–1.93)

0.838

CHA2DS2-VASc, median (IQR)

4.00(4–5)

4.0(4–5)

0.360

Infarct volume, ml, median (IQR)

51(29–76)

81(50–127)

<0.001

CURB-65 score, median (IQR)

2(1–2)

2(1–3)

0.005

Females, n(%)

88(47.06)

123(53.95)

1.32 (0.89–1.94)

0.163

Male, n(%)

99(52.94)

105(46.05)

1.32 (0.89–1.94)

0.163

BMI ≥ 24 kg/m, n(%)

55(29.41)

68(29.82)

1.02(0.67–1.56)

0.927

Hypertension, n(%)

120(64.17)

145(63.60)

0.98(0.65–1.46)

0.904

Current Smoking, n(%)

51(27.27)

75(32.89)

1.31(0.86–2.00)

0.215

Current alcohol drinking,n(%)

66(35.29)

81(35.53)

1.01(0.67–1.51)

0.961

Diabetes, n(%)

58(31.01)

65(28.51)

0.89(0.58–1.35)

0.578

Hyperlipidemia, n(%)

121(64.71)

157(68.86)

1.21(0.80–1.82)

0.371

Family history of stroke, n(%)

46(24.60)

48(21.05)

0.82(0.52–1.30)

0.390

Thrombolytic therapy, n(%)

26(13.90)

25(10.96)

0.76(0.42–1.37)-

0.763

Thrombectomy, n(%)

10(5.35)

13(5.70)

1.07(0.46–2.50)

0.875

Thrombolytic therapy+ Thrombectomy, n(%)

4(2.14)

4(1.75)

0.82(0.20–3.31)

0.777

 Antihypertensive, n(%)

96(51.34)

133(58.33)

1.38(0.90–1.96)

0.154

 Anticoagulant, n(%)

61(32.62)

21(9.21)

0.21(0.12–0.36)

0.000

 Antiplatelets, n(%)

54(28.88)

55(24.12)

0.78(0.51–1.21)

0.274

 Lipid-lowering medications, n(%)

109(58.29)

132(57.89)

0.98(0.67–1.46)

0.935